Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 6—June 2004


Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori–Infected Persons, United States

William M. Duck*, Jeremy Sobel*, Janet M. Pruckler*, Qunsheng Song*, David L. Swerdlow*, Cindy R. Friedman*, Alana Sulka*, Balasubra Swaminathan*, Tom Taylor*, Mike Hoekstra*, Patricia M. Griffin*, Duane Smoot†, Rick Peek‡, DavidC. Metz§, Peter B. Bloom¶, Steven Goldschmid¶, Julie Parsonnet#, George Triadafilopoulos#, Guillermo I. Perez-Perez**, Nimish Vakil††, Peter Ernst‡‡, Steve Czinn§§, Donald Dunne§§, and Ben D. Gold*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Howard University Medical Center, Washington, DC, USA; ‡Vanderbilt University Medical Center, Nashville, Tennessee, USA; §University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA; ¶Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA; #Stanford University Medical Center, Palo Alto, California, USA; **New York University School of Medicine, New York, New York, USA; ††Sinai Samaritan Medical Center, Milwaukee, Wisconsin, USA; ‡‡University of Virginia, Charlottesville, Virginia, USA; §§University Hospitals of Cleveland, Cleveland, Ohio, USA; ¶¶Indiana University Medical Center, Indianapolis, Indiana, USA

Main Article

Table 5

Phase I multivariate analysis of risk factors for resistance to >1 antimicrobial agent among H. pylori isolates submitted to HARP, 1998–2002a

Exposure Odds ratio (95% CI)
Patient treated another time for infection
6.0 (2.0–20)
Took Mylanta in last 12 mo
0.3 (0.1–0.8)
HARP site

New York, NY
0.2 (0.1–0.7)
Palo Alto, CA
0.2 (0.1–0.7)
Atlanta, GA
0.2 (0.1–0.6)
Nashville, TN 0.4 (0.2–0.9)

aN = 347; HARP, Helicobacter pylori Antimicrobial Resistance Monitoring Project; CI, confidence interval.

Main Article